Bio report, page-42

First 42 Last

Share
Profile

Follow
Dtermin8n

45 Posts.

19/06/14

11:18

Post #: 13544478
Share

Originally posted by hottod ↑

Thanks for picking me up on my flawed logic and obviously biased and unreasonable views, Playez.

To recap, I believed that there was pharma interest in licensing the TPM oxymorphone patch and I was not overly concerned by the fact that there hasn't yet been a licence deal announced. My view was based on the fact that both the CEO and CSO stated at the AGM in late May that there was continuing interest in the patch from multiple pharmas. My view was also influenced by expert guidance that it takes somewhere between 9 months to 2 years to get a pharma signature on a licencing deal and my calculation that it is less than 8 months since the announcement of the trial data on which negotiations will be based. Furthermore, because I trust Harry Rosen's intelligence and integrity, I naturally assumed that he would respect both pharma confidentiality and ASX listing requirements.

In contrast, you concluded that no feedback from a scientific meeting which was held in the US on May1 signifies that pharma is either underwhelmed by POH's trial data or overwhelmed by the asking price. Whichever, you interpreted the perceived “ominous silence” as suggestive of no pharma interest and no forthcoming deal. Using your logic, the CEO and CSO must have been deceiving shareholders by stating at the AGM in late May that there was ongoing pharma interest. What’s more, according to your thought processes, it’s Simon Marais who decides what Harry Rosen can or can’t disclose to the market, and if there really was an interested party, Rosen would have confided that to Marais, who would have insisted Rosen announce that to the market…

Your thinking is so darkly disturbing that, logically, you would no longer hold in this company…except that you do.

( BTW Playez, don't be too upset by lack of feedback from 2014 PainWeek as it's not being held until September. You probably confused it with The American Pain Society’s Annual Scientific Meeting, which was held in April/May. But I suspect that getting factual details correct doesn't count for much in your world).

Expand

"However Playez your strategy has always and continues to be one of casting doubt"

Devil’s advocate it actually works, not a bad strategy safer than having tunnel vision… but KC you may not understand that either, as It becomes too personal and hits a raw nerve.
Oh how I miss the Down Thumb Option!!! ...Yes I was one of the notorious down thumber’s when I disagreed with the tripe being fed

POH Price at posting: 8.3¢ Sentiment: None Disclosure: Not Held
4 Upvote

0 Great analysis

Reply

Top Stories

CNB

Carnaby Resources hits copper at Mohawk, QLD

CBL

Control Bionics expands into UK and Irish markets with NeuroNode device

GDC

Global Data Centres not clear on future operations after AirTrunk sale payout

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

YAL

Yancoal makes it into the ASX200 in latest S&P rebalance

There are more pages in this discussion • 7 more messages in this thread...

First 42 Last

Add AVE (ASX) to my watchlist

(20min delay)
Last 0.2¢		Change -0.001(20.0%)		Mkt cap ! $6.338M

Open	High	Low	Value	Volume
0.3¢	0.3¢	0.2¢	$68.62K	33.31M

Buyers (Bids)

No.	Vol.	Price($)
41	36020232	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	43250695	24

View Market Depth

No.	Vol.	Price($)
41	36020232	0.002
17	76595009	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	43000695	23
0.004	15020712	15
0.005	22033532	10
0.006	19255067	9
0.007	5722471	6

Last trade - 13.47pm 09/09/2024 (20 minute delay)

AVE (ASX) Chart

Bio report, page-42

Carnaby Resources hits copper at Mohawk, QLD

Control Bionics expands into UK and Irish markets with NeuroNode device

Global Data Centres not clear on future operations after AirTrunk sale payout

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Yancoal makes it into the ASX200 in latest S&P rebalance

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Bio report, page-42

Top Stories

Carnaby Resources hits copper at Mohawk, QLD

Control Bionics expands into UK and Irish markets with NeuroNode device

Global Data Centres not clear on future operations after AirTrunk sale payout

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Yancoal makes it into the ASX200 in latest S&P rebalance

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News